Content		Page No.
Title page		i
Candidates declaration		ii
Abstract		iii-vii
Acknowledgements		viii-ix
Dedication		x
Table of contents		xi-xxiv
List of figures		xxv-xxix
List of tables		xxx-xxxiii
List of publications during Ph.D.		xxxiv-xlii
List of abbreviations		xliii-xlvi
CHAPTER-1: INTRODUCTION		1-23
1.1.	Malaria: The prevalence.	1
1.2.	Malaria: The disease.	2-3
1.3.	Malaria: The therapeutic armamentarium.	3-5
1.4.	The artemisnins.	5-8
1.5.	Solubility enhancement: The integrated approaches for formulation development.	8-19
1.6.	Quality by Design.	19-23
CHAPTER-2: REVIEW OF LITERATURE		24-63
2.1.	Malaria.	24
2.2.	History of malaria.	25
2.3.	Treatment of malaria.	26
2.4.	Arteether.	29
2.5.	Solubility of arteether.	32
2.6.	Solubility enhancement techniques.	32
2.7.	Inclusion complexation using cyclodextrin for improved solubility.	35
2.8.	Nano-formulation for solubility enhancement.	42
2.9.	Solid Lipid Nanoparticles.	44
2.10.	Nanostructured Lipid Carriers.	45
2.11.	Self-Micro Emulsifying Drug Delivery System.	47
2.12.	Extrusion /spheronization.	49

2.13. Enteric coated tablets/ capsules. 50
2.14. Design of Experiment and Total Quality Management using QbD. 51
2.15 Relevant studies at mentor's lab
CHAPTER-3: RESEARCH ENVISAGED AND PLAN OF WORK 59-64
3.1. Problem formulation. 59
3.1.1. Research formulation. 59
3.2. Aim and objective. 59-60
3.2.1. Aim 59
3.2.2. Specific research objectives [As approved by Department Doctoral Research Committee (DDRC)] 60
3.3. Plan of work. 60-64
3.3.1. Methodology adopted. 60-64
3.4. The expected outcomes. 64
CHAPTER-4: MATERIALS AND METHODS 64-117
4.1. Materials. 64-67
4.2. Calibration of glassware and instruments. 68
4.2.1. Calibration of thermometer. 68
4.2.2. Calibration of measuring cylinder. 68
4.2.3. Calibration of analytical balance. 68
4.2.4. Calibration of pipettes. 68
4.2.5. Calibration of pH meter. 68
4.2.6. Calibration of UV spectrophotometer. 68
4.3. Preformulation studies. 69-80
4.3.1. Drug identification. 69
4.3.2. Physical appearance. 69
4.3.3. Melting point. 70
4.3.4. Solubility studies. 70
4.3.5. FT-IR spectroscopy. 70
4.3.6. DSC analysis. 70
4.3.7. XRD analysis. 70-71
4.3.8. Quantitative analysis using UV spectroscopy. 71-74
4.3.8.1. Standard stock solution. 71
4.3.8.2. Design of method. 72

4.3.8.3. Development of method. 72
4.3.8.4. Risk assessment. 72
4.3.8.5. Experiment Design. 72-73
4.3.8.6 Method design output. 73-74
4.3.8.7. Validation of Experimental Design. 74
4.3.8.8. Condition for spectroscopy. 74
4.3.8.9. Method validation. 74-76
4.3.8.9.1. Linearity analysis. 75
4.3.8.9.2. Precision. 75
4.3.8.9.3. Accuracy. 75
4.3.8.9.4. Robustness and ruggedness. 75-76
4.3.8.9.5. Detection and quantification limits (UV spectroscopy). 76
4.3.9. Quantitative analysis using HPLC. 76-80
4.3.9.1. HPLC method design. 76
4.3.9.2. HPLC method performance ratios. 76
4.3.9.3. Understanding HPLC method. 76
4.3.9.4. HPLC method risk assessment. 76-77
4.3.9.5. HPLC method experimental design. 77-80
4.3.9.5.1. HPLC method design output. 77-78
4.3.9.5.2. Chromatography conditions. 78-79
4.3.9.5.3. Validation of the proposed HPLC method. 79-80
4.3.9.5.3.1. Linearity (HPLC method). 79
4.3.9.5.3.2. Precision (HPLC method). 79
4.3.9.5.3.3. Accuracy (HPLC method). 79-80
4.3.9.5.3.4. Robustness (HPLC method) 80
4.3.9.5.3.5. Detection and quantification limits 80

(HPLC method).
4.3.9.5.3.6. Percentage purity (HPLC method). 80
4.4. Solubility enhancement techniques. 80-87
4.4.1. Hydrotropic solubilization of arteether. 80-81
4.4.1.1 Mixed hydrotropic solubilization. 81
4.4.2. Solid Dispersion. 81-83
4.4.2.1. Solvent evaporation method. 81-82
4.4.2.2. Melting procedure. 82
4.4.2.3. Characterization of solid dispersion and hydrotropic solid dispersion. 82-83
4.4.2.4. Permeability studies of prepared solid dispersion. 83
4.4.3. Cyclodextrin complexation. 83-87
4.4.3.1. Optimization of prepared cyclodextrin complexes. 83-84
4.4.3.2. Analysis of phase solubility of ART-CD complex. 84
4.4.3.3. Preparation of ART -β-CD both binary and ternary complexes. 84-85
4.4.3.4. Evaluation of CD inclusion complexes. 85-87
4.4.3.4.1. Percentage of practical yield of ART-CD complex. 85-86
4.4.3.4.2. Dissolution test analysis of ART-CD complex. 86
4.4.3.4.3. Drug content of ART-CD complex. 86
4.4.3.4.4. Saturation solubility study of ART-CD complex. 86
4.4.3.4.5. Scanning Electron Microscopy analysis of ART-CD complex. 86-87
4.4.3.4.6. Study of X-ray Diffraction of ART-CD complex. 87
4.4.3.4.7. Differential Scanning Calorimetry of ART-CD complex. 87
4.5. Formulation development and characterization. 87-117
4.5.1. Formulation optimization and development of SLNs. 87-92

4.5.1.1 Risk assessment studies for preparation of SLNs. 87
4.5.1.2. Outlining Quality Target Product Profile and CQAs for preparation of SLNs. 87-88
4.5.1.3. Preparation of solid lipid nanoparticles. 88
4.5.1.4. Optimization of SLNs by Design of experiments. 88-89
4.5.1.5. Physicochemical characterization of ART-loaded SLN. 89-92
4.5.1.5.1. Particle size analysis and polydispersity index studies of ART-loaded SLNs. 89
4.5.1.5.2. Morphology of ART-loaded SLNs. 89
4.5.1.5.3. Entrapment Efficiency % of ART-loaded SLNs. 90
4.5.1.5.4. Determination of total drug content of ART-loaded SLNs. 90
4.5.1.5.5. Determination of pH of lyophilized ART-loaded SLNs. 90
4.5.1.5.6. Particle size analysis of lyophilized ART-loaded SLNs. 90
4.5.1.5.7. Flow properties of lyophilized ART-loaded SLNs. 90-92
4.5.1.5.8. *In-vitro* release studies of lyophilized ART-loaded SLNs. 92
4.5.2. Formulation development, optimization, and characterization of NLCs. 92-96
4.5.2.1. Risk assessment studies of NLCs. 92-96
4.5.2.2. Outlining quality target product profile and CQAs of NLCs. 93
4.5.2.3. Preparation of ART Loaded NLCs. 93
4.5.2.4. Central composite design for systematic optimization of NLCs. 94
4.5.2.5. Characterization of optimized NLCs. 94-96
4.5.2.5.1. Particle size, zeta potential, and PDI of NLCs. 94
4.5.2.5.2. Evaluation of surface topography of 95

lyophilized NLCs.
4.5.2.5.3. Flow properties of lyophilized NLCs. 95
4.5.2.5.4. Drug entrapped and drug loading of lyophilized NLCs. 95
4.5.2.5.5. Drug release studies of lyophilized NLCs. 95-96
4.5.3. Self-Micro Emulsifying Drug Delivery Systems (SMEDDS). 96-104
4.5.3.1. Formulation optimization and development of SMEDDS. 96-97
4.5.3.1.1. Risk assessment studies of SMEDDS. 96
4.5.3.1.2. Outlining Quality Target Product Profile (QTPP) and CQAs of SMEDDS. 96
4.5.3.1.3. CMA of SMEDDS. 96
4.5.3.1.4. CPP of SMEDDS. 97
4.5.3.2. Formulation development, optimization, and characterization of SMEDDS. 97-100
4.5.3.2.1. Equilibrium solubility studies of ART. 97
4.5.3.2.2. Constituents of SMEDDS. 98-99
4.5.3.2.2.1. Solubility studies for screening of oil. 98
4.5.3.2.2.2. Surfactant screening through emulsification. 98
4.5.3.2.2.3. Emulsification of the maximal oil quantity Possible. 98-99
4.5.3.2.2.4. Co-surfactant screening through emulsification. 99
4.5.3.2.2.5. Emulsification of the maximal oil quantity possible with both 99

surfactant and cosurfactant.
4.5.3.2.3. Construction of ternary phase diagram. 99
4.5.3.2.4. Drug-excipients compatibility studies for preparation of SMEDDS. 100
4.5.3.3. SMEDDS development. 100-104
4.5.3.3.1. Selection of design for SMEDDS. 101
4.5.3.3.2. Visual evaluation of SMEDDS. 101-102
4.5.3.3.3. Size of globules and zeta potential of SMEDDS. 102
4.5.3.3.4. Determination of percentage drug entrapped in SMEDDS. 102
4.5.3.3.5. High-resolution Transmission Electron Microscopy of SMEDDS. 102
4.5.3.3.6. Determination of total drug content of SMEDDS. 102
4.5.3.3.7. Determination of pH of prepared SMEDDS. 103
4.5.3.3.8. Determination of drug release (%) from SMEDDS. 103
4.5.3.3.9. Thermodynamic stability studies/stability under centrifugation of SMEDDS. 103
4.5.3.3.10. Encapsulation of solid SMEDDS loading in enteric-coated capsule shells. 103-104
4.5.4. Encapsulating of spheroids containing CD complexed ART in enteric capsule shells. 104-108
4.5.4.1 Evaluation of spheroids containing CD inclusion complexed ART. 104
4.5.4.2. QbD-based analysis for the optimization development of spheroids. 105-106
4.5.4.3. Physicochemical characterization of optimized spheroids. 107-108

4.5.4.3.1. Flow properties of ART-CD spheroids. 107
4.5.4.3.2. Disintegration time of ART-CD spheroids. 107-108
4.5.4.3.3 *In -Vitro* drug release from ART-CD spheroids. 108
4.5.5. Enteric-coated tablets. 108-117
4.5.5.1. Quality profiling and identification of QTPP, CQAs, and CPPs of enteric coated tablets. 108-109
4.5.5.2. Risk assessment of enteric coated tablets. 109
4.5.5.3. Formulation development of enteric-coated tablets. 109-111
4.5.5.4. Formulation by Design strategy for optimization of critical variables of enteric coated tablets. 111-112
4.5.5.5. Defining of design space for enteric coated tablets. 112
4.5.5.6. Validation of model of enteric coated tablets. 112
4.5.5.7. In-process quality control evaluation of enteric coated tablets. 112-113
4.5.5.7.1. Flow properties of enteric coated tablets premix powder. 113
4.5.5.8. Finished product quality control evaluation of enteric coated tablets. 113-114
4.5.5.8.1. Weight variation test of enteric coated tablets. 113
4.5.5.8.2. Hardness of enteric coated tablets. 113
4.5.5.8.3. Friability of enteric coated tablets. 114
4.5.5.8.4 Content uniformity of enteric coated tablets 114
4.5.5.9. *In -vitro* release studies of the enteric-coated tablets. 114-115
4.5.5.10. Permeability studies of prepared formulations. 115
4.5.5.11. *Ex-vivo* studies of prepared formulations. 115-116
4.5.5.12. *In- vivo* studies of prepared formulations. 116-117
4.5.5.12.1. Sample preparation. 116
4.5.5.12.2. Pharmacokinetics and biostatistics. 116-117
Chapter- 5 RESULTS AND DISCUSSIONS 118-222

5.1. Calibration of glassware and instruments. 118
5.1.1. Calibration of thermometer. 118
5.1.2. Calibration of measuring cylinder. 118
5.1.3. Calibration of analytical balance. 118-119
5.1.4. Calibration of pipettes. 119
5.1.5. Calibration of pH meter. 119
5.1.6. Calibration of UV spectrophotometer. 120-121
5.1.6.1. Limit of stray light. 120
5.1.6.2. Resolution power. 120
5.1.6.3. Control of absorbance. 120-121
5.2. Preformulation study. 121-139
5.2.1. Physical appearance. 121
5.2.2. Melting point. 121
5.2.3. Solubility studies. 121-122
5.2.4. FT-IR spectroscopy. 122
5.2.4.1. FT-IR analysis of ART. 122
5.2.5. DSC analysis. 122
5.2.5.1. DSC of ART. 122
5.2.6. XRD analysis of ART. 123
5.2.7. UV spectroscopy. 124-132
5.2.7.1. Determination of wavelength. 125
5.2.7.2. Experimental design. 125-127
5.2.7.3. Statistical optimization data analysis based on QbD. 127
5.2.7.4. Equating responses are equated in terms of coded variables. 127-129
5.2.7.5. Experimental model validation. 130-132
5.2.7.5.1. Linearity. 130
5.2.7.5.2. Precision. 130-131
5.2.7.5.3. Accuracy. 131
5.2.7.5.4. Robustness. 131
5.2.7.5.5. LOD and LOQ. 131-132
5.2.8. Quantitation of ART using HPLC method. 132-139
5.2.8.1. Experimental design optimization and response 132-133

surface methodology for HPLC method.
5.2.8.2. ANOVA-based statistical analysis for HPLC method. 134-136
5.2.8.3. The proposed model's point prediction and validation. 136-139
5.2.8.3.1. Linearity (HPLC method). 137-138
5.2.8.3.2. Accuracy (HPLC method). 138
5.2.8.3.3. Precision (HPLC method). 138-139
5.2.8.3.4. Precision (intraday and interday) (HPLC method). 139
5.2.8.3.5. Limit of detection (LOD) and limit of quantification (LOQ) (HPLC method). 139
5.3. Solubility enhancement. 140-157
5.3.1. Characterization of prepared hydrotropic solid dispersions. 140
5.3.1.1. Solubility studies of prepared hydrotropic solid dispersion. 140
5.3.2. Differential scanning calorimetry of prepared hydrotropic solid dispersion. 140-141
5.3.3. FT-IR spectroscopy of prepared hydrotropic solid dispersion. 141-142
5.3.4. X-Ray diffraction studies of prepared hydrotropic solid dispersion. 142
5.3.5. Characterization of prepared solid dispersions. 143-150
5.3.5.1. Solubility studies of the prepared solid dispersions. 143-145
5.3.5.2. Dissolution studies of the prepared solid dispersions. 145-146
5.3.5.3. Differential scanning calorimetry of the prepared solid dispersions. 146-147
5.3.5.4. FT-IR spectroscopy of the prepared solid dispersions. 148-149
5.3.5.5. X-Ray diffraction studies of the prepared solid dispersions. 149
5.3.5.6. Permeability studies of the prepared solid dispersions. 150

5.3.6. Preparation and characterization of inclusion complexes. 150-157
5.3.6.1. Solubility studies of inclusion complexes. 151
5.3.6.2. Dissolution studies of inclusion complexes. 151-152
5.3.6.3. FT-IR spectroscopy of inclusion complexes. 152-153
5.3.6.4. Mass spectroscopy of inclusion complexes. 153-154
5.3.6.5. Differential scanning calorimetry of inclusion complexes. 154-155
5.3.6.6. SEM image analysis of ART and inclusion complexes. 155-157
5.4. Formulation development. 158-218
5.4.1. Formulation development, optimization, and characterization of SLNs. 158-172
5.4.1.1. Formulation development and optimization of SLNs. 158-161
5.4.1.1.1. Risk assessment studies of SLNs. 158
5.4.1.1.2. Outlining quality target product profile and CQAs of SLNs. 158-159
5.4.1.1.3. Preparation of SLNs. 159
5.4.1.1.4. Selection of lipids for SLNs. 160
5.4.1.1.5. Risk assessment studies for SLNs. 160-161
5.4.1.1.6. Design of Experiments for SLNs. 161
5.4.1.2. Optimization and development of SLNs. 161-172
5.4.1.2.1. DoE-based optimization of selected factors. 161-162
5.4.1.2.2. Statistical analysis of data of SLNs. 162-163
5.4.1.2.3. Effect of the variables on entrapment efficiency of SLNs. 163-164
5.4.1.2.4. Effect of the variables on particle size of SLNs. 164-165
5.4.1.2.5. Overlay plot and validation of model of SLNs. 165-166
5.4.1.2.6. Preparation of solid SLNs. 166
5.4.1.2.7. Physicochemical characterization of 166-170

lyophilized ART- loaded SLNs.
5.4.1.2.7.1. Particle size distribution of lyophilized SLNs. 167
5.4.1.2.7.2. Surface morphology of lyophilized SLNs. 167-168
5.4.1.2.7.3. XRD of lyophilized SLNs. 168
5.4.1.2.7.4. Entrapment efficiency % of lyophilized SLNs. 168
5.4.1.2.7.5. pH of lyophilized SLNs. 168
5.4.1.2.7.6. Particle size distribution of lyophilized SLNs. 169
5.4.1.2.7.7. Shape of lyophilized SLNs. 169-170
5.4.1.2.7.8. *In-vitro* drug release of lyophilized SLNs. 170
5.4.1.3. Discussion on SLNs. 171-172
5.4.2. Formulation development, optimization and characterization of nano lipid colloids. 172-182
5.4.2.1. Formulation, optimization and development. 172-182
5.4.2.1.1. Selection of lipids for NLCs. 172
5.4.2.1.2. Risk assessment studies for NLCs. 172-175
5.4.2.1.3. Reduced quadratic Model – ANOVA for preparation of NLCs. 175-178
5.4.2.1.4. Validation of the proposed model for NLCs. 178
5.4.2.1.5. Formulation development of NLCs. 179
5.4.2.1.6. Characterization of NLCs. 179-182
5.4.2.1.6.1. Morphology of NLCs. 179-180
5.4.2.1.6.2. Particle size distribution of lyophilized NLCs. 180

5.4.2.1.6.3. Shape of lyophilized NLCs. 180-181
5.4.2.1.6.4. Entrapment efficiency in lyophilized NLCs. 181
5.4.2.1.6.5. *In -vitro* drug release of lyophilized NLCs. 181-182
5.4.2.2. Discussion on ART-NLC. 182
5.4.3. Formulation development, optimization and characterization of self micro emulsified drug delivery systems. 182-196
5.4.3.1. Formulation optimization and development for SMEDDS. 182-192
5.4.3.1.1. Equilibrium solubility studies for SMEDDS. 182-183
5.4.3.1.2. Solubility in solvents, oils, and surfactants for SMEDDS. 183-185
5.4.3.1.3. Construction of the ternary phase diagram for SMEDDS. 185-187
5.4.3.1.4. Risk assessment studies of SMEDDS. 187-189
5.4.3.1.5. Selection of design of SMEDDS. 189-192
5.4.3.1.5.1. Measurement of dependent responses for SMEDDS. 189-190
5.4.3.1.5.2. ANOVA based statistical analysis of data for SMEDDS. 190-191
5.4.3.1.5.3. Overlay plot and validation of the model for SMEDDS. 191-192
5.4.3.2. Characterization of SMEDDS. 192-195-195
5.4.3.2.1. Visual appearance of SMEDDS. 192
5.4.3.2.2. Microscopic image of SMEDDS. 193
5.4.3.2.3. Globule size analysis of SMEDDS. 193

5.4.3.2.4. Shape of solidified-SMEDDS. 194-195
5.4.3.2.5. *In- vitro* drug release of S-SMEDDS. 195
5.4.3.3. Discussion on SMEDDS. 195-196
5.4.4. Formulation development optimization and characterization of CD complex containing spheroids. 196-207
5.4.4.1. Experimental design optimization and response surface methodology for spheroids. 196-197
5.4.4.2. Equation of responses in terms of coded factors for spheroids. 198
5.4.4.3. ANOVA-based statistical analysis for spheroids. 198-201
5.4.4.4. Overlay plot and defining the design space for spheroids. 201-202
5.4.4.5. Point prediction and validation of developed model for spheroids. 202
5.4.4.6. Flow properties of spheroids. 202-204
5.4.4.7. *In-vitro* drug release of CD complex containing spheroids. 204-205
5.4.4.8. Morphology of CD complex containing spheroids. 205-206
5.4.4.9. Discussion on spheroids. 206-207
5.4.5. Formulation development, optimization, and characterization of enteric coated tablets. 207-218
5.4.5.1. Statistical optimization of enteric-coated tablets. 207-208
5.4.5.2. Selection of critical ingredients using Plackett-Burman design for enteric-coated tablets. 208
5.4.5.3. Response surface methodology for enteric-coated tablets. 209
5.4.5.4. Statistical analysis of mathematical model for enteric-coated tablets. 209-210
5.4.5.5. ANOVA for quadratic model for enteric-coated tablets containing CD complexed ART. 210-212
5.4.5.6. Contour plots and optimization for enteric-coated tablets 212-213

5.4.5.7. Validation of model for enteric-coated tablets. 213-215
5.4.5.8. Evaluation of enteric-coated tablets. 215-218
5.4.5.8.1. Particle size distribution. 215
5.4.5.8.2. Flow properties of powder (IPQC). 215-216
5.4.5.8.3. Finished product quality control evaluation of enteric coated tablets. 216-217
5.4.5.8.4. Discussion on enteric coated tablets. 218

5.5. Comparative permeability studies of prepared formulations. 219
5.6. Pharmacokinetic study of ART and all prepared formulations. 220-221
5.7. Antimalarial activity. 221-222

6. SUMMARY AND CONCLUSION 223-228

BIBLIOGRAPHY 229-259

Brief Bio-data